Navigation Links
TEI Biosciences' PriMatrix(TM) Awarded Seal of Approval by American Podiatric Medical Association
Date:2/18/2010

BOSTON, Feb. 18 /PRNewswire/ -- TEI Biosciences Inc. announced today that its PriMatrix™ Dermal Repair Scaffold has been awarded the coveted American Podiatric Medical Association's (APMA) Seal of Approval.  PriMatrix is a bioactive collagen matrix used in the management of diabetic and venous ulcers, second-degree burns, and surgical and trauma wounds.

APMA is the nation's leading professional society for foot and ankle specialists. The Seal of Approval Program was created to inform podiatric physicians and consumers about products whose quality, safety, and effectiveness promote good foot health.  In order to qualify for the Seal of Approval, PriMatrix had to pass a thorough scientific evaluation by a panel of APMA members. The results were then evaluated by a committee of Doctors of Podiatric Medicine who decided to grant TEI the use of the Seal for PriMatrix.

"TEI is very excited about APMA's Seal of Approval award for PriMatrix," said Yiannis Monovoukas, Ph.D., TEI's Chairman, President and CEO.  "PriMatrix is a novel biologic product proven safe and effective in treating many types of skin wounds in several thousand patients," said Dr. Monovoukas.  "The addition of the APMA's Seal of Approval to PriMatrix is an affirmation of our commitment to developing innovative healthcare products that better meet the needs of physicians and their patients."  

About PriMatrix™ Dermal Repair Scaffold

PriMatrixDermal Repair Scaffold is an acellular collagen matrix derived from fetal bovine dermis, one of the purest forms of collagen available. Due to its bioactive collagen matrix technology, PriMatrix is an ideal material for the management of numerous types of wounds as it supports cell repopulation and revascularization processes essential to wound healing. PriMatrix is rich in Type III collagen, a natural component of fetal dermis that aids in tissue healing and regeneration.

PriMatrix is intended for the management of wounds that include: partial and full thickness wounds; pressure, diabetic, and venous ulcers; second-degree burns; surgical wounds; trauma wounds; tunneled/undermined wounds; and draining wounds.  

For more information, please visit TEI's website at www.teibio.com.

About TEI Biosciences Inc.

A Boston-based, privately-held, leading biomedical company, TEI Biosciences Inc. has applied its expertise in regenerative medicine to develop and commercialize novel biologic products for a broad spectrum of soft tissue repair, regeneration, and reinforcement applications -- from plastic and reconstructive surgery to dura, tendon, and hernia repair, and wound management.

TEI sells its products directly and through partnerships with some of the world's major medical device companies.  TEI's marketed products include:

  • SurgiMend® for plastic and reconstructive surgery, breast reconstruction, muscle flap reinforcement, hernia repair, and abdominal wall reconstruction;
  • PriMatrix™ for skin wound management;
  • Durepair® for cranial and spinal dura mater repair (marketed by Medtronic);
  • Xenform™  for pelvic floor reconstruction (marketed by Boston Scientific);
  • TissueMend® for tendon augmentation (marketed by Stryker).

SOURCE TEI Biosciences Inc.

RELATED LINKS
http://www.teibio.com

'/>"/>

SOURCE TEI Biosciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. YM BioSciences presents CYT387 and CYT997 data at international cancer conference
2. YM BioSciences granted two US patents for AeroLEF(R)
3. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
4. YM BioSciences reports second quarter 2010 operational and financial results
5. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
6. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
7. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
8. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
9. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
10. YM BioSciences announces result of Cytopia shareholder vote
11. Profectus Biosciences to Present at Key Investor Conference in January 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... PBI-Gordon Corporation is pleased to announce Doug ... Doug began his career at PBI-Gordon in February 1988, after finishing his masters in ... roles, ranging from customer service to national product manager, to helping develop, name and ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... enterprise talent development, skill-building and compliance training platform on mobile devices, today ... course: Overview of Regulatory Requirements for Medical Devices. The course is essential for ...
(Date:5/3/2016)... ... 2016 , ... Flagship Biosciences, the leader in tissue ... of Directors. Dr. Gillett recently retired from Charles River Laboratories (CRL), where, in ... Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River in 1999 through ...
(Date:5/3/2016)... -- - And Other Rising Companies - ... Competitor Biologics  - Biosimilar Drug Producers - ... Who are the most important and promising ... sales potentials? Discover, in our updated survey, organisations, outlooks ... revenue forecasting. Visiongain,s new study ...
Breaking Biology Technology:
(Date:3/14/2016)... 2016 http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ... --> DERMALOG, le leader de ... lecteurs d,empreintes digitales pour l,enregistrement des réfugiés en ... pour produire des cartes d,identité aux réfugiés. DERMALOG ...
(Date:3/10/2016)... PUNE, India , March 10, 2016 ... to a new market research report "Identity and Access ... SSO, & Audit, Compliance, and Governance), by Organization Size, ... Forecast to 2020", published by MarketsandMarkets, The market is ... to USD 12.78 Billion by 2020, at a Compound ...
(Date:3/9/2016)... 2016 Nigeria . ... than 23,000 public service employees either did not exist ... salary unlawfully.    --> Nigeria ... more than 23,000 public service employees either did not ... their salary unlawfully.    --> DERMALOG, the ...
Breaking Biology News(10 mins):